

**PARTNERSHIP HEALTHPLAN OF CALIFORNIA (PARTNERSHIP)  
MEETING MINUTES**

**Committee:** Physician Advisory Committee  
**Date / Time:** August 12, 2026 - 7:30 to 9:00 a.m.

*Voting members are required to attend in-person at one of Partnership HealthPlan's posted locations.*

|                  |                                                                                                                                                                  |                                                                                                                                                           |                                                   |                                                                                |                                                                                        |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Members Present: | Angela Brennan, DO (FF)<br>Brian Montenegro, MD (FF)<br>Michelle Herman, MD (FF)<br>Steven Gwiazdowski, MD (FF)<br>Teresa Shinder, MD (FF)<br>Zoe Cappe, MD (FF) | Candy Stockton, MD (E)<br>Chris Myers, MD, (E)<br>Malia Honda, MD (E)<br>John McDermott, FNP (C)<br>Darrick Nelson, MD (R)<br>Leigh Vall-Spinosa, MD (SR) | Mills Matheson, MD (OMM)<br>Derice Seid, MD (MCC) | FF Fairfield<br>SR Santa Rosa<br>E Eureka<br>R Redding<br>C Chico<br>AU Auburn | MCC Marin Community Clinics<br>OMM Office of Dr. Matheson<br>SL Sutter Health Lakeside |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|

|                  |                                                |                                         |                      |
|------------------|------------------------------------------------|-----------------------------------------|----------------------|
| Members Excused: | Karen Sprague, MSN, CFNP<br>Chester Austin, MD | Matthew Zavod, MD<br>Betabel Kunkel, MD | Christina Lasich, MD |
|------------------|------------------------------------------------|-----------------------------------------|----------------------|

|                 |                                        |
|-----------------|----------------------------------------|
| Members Absent: | Danielle Oryn, DO<br>Karina Gookin, MD |
|-----------------|----------------------------------------|

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Partnership Staff: | Sonja Bjork, Chief Executive Officer<br>Jennifer Lopez, Chief Financial Officer<br>Wendi Davis, Chief Operating Officer<br>Leigha Andrews, Region Director<br>Vicky Klakken, Region Director<br>Brigid Gast, RN, Sr. Dir., Care Management<br>Aaron Brincko, Sr. Dir., Provider Relations<br>Lisa O'Connell, Dir. Enhanced Health Services<br>Doreen Crume, RN, Mgr. Care Coord.<br>Stephanie Nakatani, Supervisor<br>Provider Relations Representatives | Katherine Barresi, RN, Chief Health Services Officer<br>Robert Moore, MD, Chief Medical Officer<br>Kermit Jones, MD, Deputy Chief Medical Officer<br>Colleen Townsend, MD, Region Medical Director<br>Jeffrey Ribordy, MD, Region Medical Director<br>Bradley Cox, MD, Region Medical Director<br>R. Doug Matthews, MD, Region Medical Director<br>Matthew Morris, MD, Region Medical Director<br>Lisa Ward, MD, Region Medical Director<br>Mark Netherda, MD, Medical Director for Quality<br>Jeffrey DeVido, MD, Behavioral Health Clinical Dir.<br>Stan Leung, Pharm.D., Director, Pharmacy Services<br>Marshall Kubota, MD, Associate Medical Director | Irem Conery, Director of Member Experience<br>DeLorean Ruffin, DrPH, Director, Population Health<br>Mohamed Jalloh, Pharm.D., Director, Health Equity<br>Isaac Brown, Sr. Dir., Quality & Performance Improvement<br>Vacant, Director, Quality Management<br>Kristine Gual, Director, Quality Measurement<br>Vacant, Manager of QI Programs<br>Sue Quichocho, Mgr., Quality Measurement<br>Megan Shelton, Project Manager, Quality Improvement<br>Vacant, RN, Director, Utilization Mgmt. (UM)<br>Kevin Jarret-Lee, RN, Assoc. Dir. of UM<br>Robby Potter, RN, Supervisor of Inpatient UM<br>David Lavine, Assoc. Dir. of Workforce Development |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| AGENDA ITEM     | DISCUSSION / CONCLUSIONS                                       | RECOMMENDATIONS / ACTION                | DATE RESOLVED |
|-----------------|----------------------------------------------------------------|-----------------------------------------|---------------|
| Public Comments | PAC Chairperson asked for any public comments. None presented. | N/A                                     | N/A           |
| Quorum          | 14/21 – PAC                                                    | Committee quorum requirements met (14). | 08/12/26      |

| AGENDA<br>ITEM                            | DISCUSSION / CONCLUSIONS<br>For information only, no formal action required.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I.A. Chief Executive Officer (CEO) Report | <p><b>Partnership’s Chief Human Resources Officer presented an administrative update on behalf of the Chief Executive Officer.</b></p> <p><b>Unsatisfactory Immigration Status (UIS) Transition to Medi-Cal Fee for Service (FFS)</b></p> <ul style="list-style-type: none"> <li>Effective January 1, 2027, members in UIS status will transition out of managed care for general Medi-Cal benefits and into the state Medi-Cal fee-for-service delivery system.</li> <li>The change affects approximately 2 million members statewide and, based on Partnership data as of August 1, approximately 84,000 Partnership members.</li> <li>The transition is a delivery-system change, not a loss of Medi-Cal eligibility for general medical benefits.</li> <li>Members affected by the transition will no longer be assigned to Partnership HealthPlan, managed care plans, or primary care providers through managed care.</li> <li>Members may seek care from any Medi-Cal fee-for-service enrolled provider who is accepting patients.</li> <li>Pharmacy benefits will continue through Medi-Cal Rx.</li> <li>Specialty mental health services and substance use disorder treatment will continue through county behavioral health systems.</li> <li>Members moving to fee-for-service will no longer be eligible for Enhanced Care Management or Community Supports.</li> <li>DHCS has released a UIS transition policy guide and is coordinating with Partnership and other managed care plans to support the transition.</li> <li>Partnership is taking the following actions in preparation for the transition: <ul style="list-style-type: none"> <li>Identifying high-risk members, including members receiving dialysis, transplant patients, members in skilled nursing facilities, and members receiving CCS services.</li> <li>Conducting outreach to high-risk members to explain upcoming changes, available options, and provider availability after January 1, 2027.</li> <li>Working with DHCS to determine what meaningful data can be shared to support continuity of care, including authorization data and patient census information.</li> <li>Advocating for DHCS to establish an escalation pathway so health plans, providers, and counties can quickly address urgent transition issues.</li> </ul> </li> <li>An internal Partnership workgroup is coordinating across the organization to support timely planning and communication with members, providers, and community stakeholders.</li> <li>Providers and members are encouraged to keep their contact information current with their county Medi-Cal eligibility office.</li> <li>Providers should ensure medically necessary treatment plans, referrals, and medication regimens are requested and reviewed before the transition date.</li> <li>Providers who want to continue serving affected members must be enrolled in Medi-Cal fee-for-service through <a href="#">PAVE</a>, the Provider Application and Validation for Enrollment process through DHCS.</li> <li>Partnership provides a county-by-county list of resources on its <a href="#">Community webpage</a> that may be helpful to members and providers during the transition.</li> </ul> <p><b>Questions</b></p> <p><b>Will Medi-Cal fee-for-service cover eConsult and telemedicine services after members transition out of managed care?</b><br/>Partnership will verify and follow up. Individual providers may be able to contract directly with eConsult vendors for multiple insurance statuses, including uninsured patients, which may be a potential workaround if Medi-Cal fee-for-service does not cover comparable services.</p> <p><b>Will specialists currently contracted with Partnership be expected or required to continue seeing members after the members transition to Medi-Cal fee-for-service?</b><br/>Contracted specialists are required to be PAVE enrolled and therefore are Medi-Cal providers; however, there is no direct requirement that they accept Medi-Cal fee-for-service rates. Continuity-of-care and patient-abandonment considerations may apply, but enforcement would likely fall to the state.</p> |

| AGENDA<br>ITEM                                               | DISCUSSION / CONCLUSIONS<br>For information only, no formal action required.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I.A Chief Executive Officer (CEO)<br>Report, Continued       | <p><b>Rural Workforce Development, Recruitment, and Retention Funding Opportunity</b></p> <ul style="list-style-type: none"> <li>• CalAIM/CalAIM-related workforce guidance had been released for a new rural workforce funding opportunity focused on workforce development, recruitment, and retention.</li> <li>• The opportunity is intended to support recruitment and retention of professionals serving rural California communities.</li> <li>• Approximately \$54.2 million is available statewide.</li> <li>• Funding may be available up to approximately \$1 million per organization or \$2 million per consortium.</li> <li>• Individual provider-related support may exceed \$150,000 and is tied to a five-year service commitment.</li> <li>• Eligible applicants include rural-serving organizations, rural hospitals, clinics, federally qualified health centers, tribal health organizations, rural collaboratives, and controlled hubs.</li> <li>• Qualifying sites must be physically located in rural areas as defined by HRSA.</li> <li>• Priority clinical personnel include professionals in primary care, maternity care, nursing, and community-based direct care, with additional eligible positions identified in the full guidance.</li> <li>• Applications are open and close on August 31, 2026.</li> <li>• Awards are anticipated in September or October 2026.</li> <li>• Partnership’s immediate focus is helping eligible organizations understand and pursue the funds so as much investment as possible remains in the region.</li> <li>• Partnership will monitor how award dollars are distributed, identify remaining workforce gaps, and evaluate how Partnership’s provider recruitment and retention initiatives can best complement the new funding.</li> </ul> <p><i>No questions asked.</i></p>                                                                                                                                                              |
| I.B Chief Medical Officer (CMO)<br>Health Services<br>Report | <p><b>Partnership’s Chief Medical Officer presented the following Health Services report.</b></p> <p><b>Strategic Planning</b></p> <ul style="list-style-type: none"> <li>• Partnership is beginning its every three-year strategic planning process.</li> <li>• The strategic planning process begins with internal review of the prior strategic plan and staff input regarding potential new focus areas, including community involvement, stakeholder interviews, input from the Community Advisory Committee, and eventual Board review and approval.</li> <li>• Board approval of the updated strategic plan is anticipated in April.</li> </ul> <p><b>Rural Health Transformation Funding</b></p> <ul style="list-style-type: none"> <li>• Funding opportunities are being released periodically, approximately one or two per month, requiring organizations to remain attentive to deadlines.</li> <li>• Partnership is not applying for grants itself and is not positioned to receive grant money; instead, Partnership is supporting efforts to bring resources into the community.</li> <li>• There are concerns among some rural hospitals that portions of the funding may be redirected to state-level administration, consultants, or non-hospital entities rather than directly supporting hospitals affected by federal funding changes.</li> <li>• Continued support for small rural hospitals remains critical.</li> </ul> <p><b>Developmental Screening for Children and Follow-up Care</b></p> <ul style="list-style-type: none"> <li>• A partnership between Chapa-De Indian Health and the UC Davis MIND Institute has a promising pilot with lessons that may be useful to the broader network.</li> <li>• A webinar on developmental screening and follow-up is planned for Monday, September 21, 2026, from noon to 1:00 p.m.</li> <li>• Organizations are encouraged to send clinical or administrative staff involved in pediatrics or pediatric developmental care.</li> </ul> |

| AGENDA ITEM                                                   | MOTIONS FOR APPROVAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | RECOMMENDATIONS / ACTION                                                                                                                                                                                  | DATE<br>RESOLVED            |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| II.A.                                                         | <b>June 10, 2026, PAC minutes were presented for approval.</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <b><u>MOTION:</u></b> Dr. Herman moved to approve Agenda II.A as presented, seconded by, seconded by Dr. Gwiazdowski.<br><b><u>ACTION SUMMARY:</u></b> [14] yes, [0] no, [0] abstentions.                 | 08/12/26<br>Motion carried. |
| II.B.<br><br>II.B.1<br><br>II.B.2<br><br>II.B.3<br><br>II.B.5 | <b>Consent Calendar Review</b><br><ul style="list-style-type: none"> <li>• Quality / Utilization Advisory Committee (QUAC) Activities Report with Attachments – June &amp; July 2026</li> <li>• Policies, Procedures, and Guidelines for Action Policy Summary, August 12, 2026</li> <li>• Pharmacy &amp; Therapeutics Advisory Committee Summary, July 9, 2026</li> <li>• Credentials Committee Meeting Summary &amp; Credentialed List, May 13, 2026<br/>Summary &amp; Credentialed List, June 10, 2026</li> </ul> | <b><u>MOTION:</u></b> Dr. Montenegro moved to approve Agenda II.B.1, II.B.2, II.B.3, and II.B.5 as presented, seconded by Dr. Herman.<br><b><u>ACTION SUMMARY:</u></b> [14] yes, [0] no, [0] abstentions. | 08/12/26<br>Motion carried. |
| VI.A                                                          | Proposed 2027 Perinatal Quality Improvement Program (QIP) Measure Set                                                                                                                                                                                                                                                                                                                                                                                                                                                | <b><u>MOTION:</u></b> Dr. Herman moved to approve Agenda item VI.A as presented, seconded by Dr. Montenegro<br><b><u>ACTION SUMMARY:</u></b> [14] yes, [0] no, [0] abstentions.                           | 08/12/26<br>Motion carried  |

| <b>AGENDA<br/>ITEM</b>                                         | <b>DISCUSSION / CONCLUSIONS</b><br>For information only, no formal action required.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| III. Executive Leadership Update, Deputy Chief Medical Officer | <p><b>Partnership’s Deputy Chief Medical Officer provided a brief report discussing additional Partnership activities.</b></p> <p><b>DHCS Clinical Efficiency Review</b></p> <ul style="list-style-type: none"> <li>The review uses inpatient, outpatient, pharmacy, and encounter data from a prior 12-month period to make prospective adjustments to managed care capitation rates. For the current review cycle, DHCS is using data from July 2024 through June 2025 to inform capitation rates beginning in 2027.</li> <li>DHCS reviews selected areas where data suggest care may be delivered more efficiently. Some perceived inefficiencies may reflect missing data rather than true clinical inefficiency, such as missing documentation of seven-day or 30-day outpatient follow-up after hospital or emergency department visits.</li> <li>Initial areas reviewed by DHCS included low-acuity non-emergent emergency department utilization, medically unnecessary cesarean sections, durable medical equipment, radiology, short inpatient stays, and cellulitis treatment. After several rounds of engagement with Partnership and other managed care plans in February, May, and June, DHCS held back on applying efficiencies related to cellulitis treatment, short inpatient stays, durable medical equipment, and radiology. Some efficiency categories may be clinically reasonable in theory, such as outpatient treatment of cellulitis, while others may function more like a broad capitation reduction; for example, DHCS identified a statewide percentage of cesarean sections it considered potentially unjustified or medically unnecessary, with regional variation across California.</li> <li>DHCS applies global exclusions to remove certain complex members from efficiency calculations, including members with HIV, trauma, extensive burns treated in the ICU, and metastatic cancer.</li> <li>For the current period, the targeted efficiency level was set at 50%, meaning that if a potential efficiency amount was calculated at \$1 million, the capitation adjustment would withhold \$500,000.</li> <li>The targeted efficiency level is expected to increase for 2028.</li> <li>Partnership will continue meeting with DHCS regarding clinical efficiencies and more detailed report will be provided at the next PAC meeting.</li> </ul> <p><b>Enhanced Provider Engagement Program</b></p> <ul style="list-style-type: none"> <li>The program originally began in 2023 and focuses on providers across the network who earned less than 25% of available PCP QIP incentives.</li> <li>Targeted engagement includes additional tools, coaching, monthly engagement, and quality improvement support.</li> <li>The program goal is to help participating providers improve performance to at least the 50% incentive level.</li> <li>Some providers in the network have already begun engaging with Partnership through the program.</li> </ul> |
| IV.A Status Update, Regional Medical                           | <p><b>Partnership’s Regional Medical Director for Napa, Solano, and Yolo Counties presented a brief update on activities.</b></p> <ul style="list-style-type: none"> <li>CommuniCare+OLE recently appointed a new Chief Medical Officer.</li> <li>La Clinica held a successful kindergarten roundup event in Vallejo, serving close to 100 children for preschool and kindergarten, which included exams, screening services, and support for children preparing to enter school. <ul style="list-style-type: none"> <li>Compared with early post-COVID kindergarten roundup events, children appeared to be presenting with fewer previously undetected developmental and physical findings.</li> <li>In prior years, many children had delayed or missed care during the COVID period, resulting in significant developmental and physical concerns identified at school-entry exams.</li> <li>This year, children with developmental concerns were more likely to already be connected to services and were reportedly doing well with those services.</li> <li>Developing a toolkit with Touro and other health centers to help practices implement similar events that would identify staffing, clinical, host-organization, and operational resources needed to conduct a successful kindergarten roundup.</li> </ul> </li> <li>The NorthBay–Providence Queen of the Valley merger continues to move forward, with implementation still anticipated for January 2027.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

| AGENDA<br>ITEM                             | DISCUSSION / CONCLUSIONS<br>For information only, no formal action required.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IV.B<br>Status Update,<br>Regional Medical | <p><b>Partnership’s Regional Medical Director for Marin and Sonoma Counties presented a brief update on activities.</b></p> <ul style="list-style-type: none"> <li>• The next Santa Rosa regional quality meeting is scheduled for September 3. The meeting theme will be chronic disease management, with a focus on the role of nursing in supporting blood pressure control.</li> <li>• The region is moving forward on Community Health Assessment/Community Health Improvement Plan (CHA/CHIP) goals related to vaccine uptake, focused on influenza vaccine uptake among children ages zero to five.</li> <li>• Dr. Mia Shim has been <a href="#">appointed Public Health Officer</a> for Sonoma County.</li> <li>• The region welcomed new family medicine resident classes at Kaiser and Sutter Santa Rosa through a dinner gathering sponsored by the Sonoma-Mendocino-Lake chapter of the California Medical Association.</li> <li>• Partnership staff recently met with the Sonoma County Economic Development Agency and Sonoma County Human Services Department regarding enrollment and work requirements. The new collaboration is intended to help coordinate efforts so members can keep Medi-Cal applications, enrollment, and reenrollment moving efficiently.</li> <li>• Two large clinics in the area that have been providing gender-affirming care are either organizing changes to their services or have ceased providing that care because of the current federal health policy environment. Those clinics are working to develop alternative collaboration and care-management pathways so affected patients can be connected to other sources of care.</li> <li>• Petaluma Health Center is opening a new site with 27 exam rooms, supported by Partnership access grant funding earlier in the year. Petaluma Health Center is also opening a new pharmacy in West Marin. Petaluma Health Center’s interim CMO is stepping down. Dr. Melissa Marshall will serve as a consultant to support Petaluma Health Center in developing the new CMO search process and job description.</li> <li>• Two clinics held back-to-school events, one at Ritter Center and one at Sonoma Valley Community Health Center. More than 350 children received backpacks, school supplies, and gift certificates through these events. Partnership member services staff attended the events to distribute Keep Your Medi-Cal campaign materials and speak with families about benefits.</li> <li>• Marin Community Clinics is closing its Larkspur site and consolidating patients into the nearby Greenbrae site.</li> <li>• Alexander Valley Healthcare reported hiring six new staff members, including two family nurse practitioners and two licensed marriage and family therapists in behavioral health. There are two promising Chief Medical Officer candidates under review after more than a year without a permanent CMO.</li> </ul> |
| IV.C<br>Status Update,<br>Regional Medical | <p><b>Partnership’s Regional Medical Director for Lake, Mendocino, Humboldt, and Del Norte Counties presented a brief update on activities.</b></p> <ul style="list-style-type: none"> <li>• Lake County is seeking a part-time public health officer.</li> <li>• In Mendocino County, Darcy Antle, the recent Director of Health and Human Services, is returning in a part-time deputy director role.</li> <li>• Mendocino County currently has an interim Health and Human Services Director and is seeking a permanent director.</li> <li>• Mendocino Community Health Clinic also has a Chief Executive Officer opening.</li> <li>• The Yurok Tribe broke ground in July on a health and wellness center near Martin’s Ferry Bridge, north of the Hoopa area. The center is expected to include inpatient and outpatient substance use disorder treatment, as well as a broad range of health and wellness services for tribal members.</li> <li>• The project was described as a significant new resource for the community.</li> <li>• The Eureka region recently hosted a long-term care appreciation luncheon for long-term care providers. The luncheon recognized the work of long-term care providers and provided an opportunity to discuss upcoming changes affecting long-term care.</li> <li>• Several small fires in the region have been contained or knocked down quickly by Cal Fire and other responding agencies. A larger fire in Hoopa Valley was reported at approximately 2,800 acres and about 10% contained as of midnight. The fire was not believed to be threatening many structures at the time of the report, but it was affecting air quality in Hoopa Valley. Agencies were working to provide air purifiers and other available support to the area.</li> <li>• The United Indian Health Services clinic in Weitchpec temporarily closed for one or two days because the highway was closed due to the fire’s proximity. Alternative routes remained available, and the clinic had reopened, although air quality remained a concern.</li> <li>• The Eureka region held its first maternity photo shoot at Sequoia Park in Eureka. The event invited pregnant members, recently postpartum members, and their families to participate in a professional photo shoot. Approximately 29 mothers and families attended. The event was conducted in coordination with the Population Health Department and supported by Population Health staff and the Eureka office team.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                     |

| AGENDA ITEM                                | DISCUSSION / CONCLUSIONS<br>ACTION REQUIRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IV.D Status Update,<br>Regional Medical    | <p><b>Partnership’s Regional Medical Director for Glenn, Butte, Sutter, and Colusa Counties presented a brief update on activities.</b></p> <ul style="list-style-type: none"> <li>• Pediatric expansion discussions are underway in the Gridley area. Chukwuemeka Ndulue MD, a private-practice pediatrician in Gridley, is expanding office hours into the evening.</li> <li>• The AAM/Orchard Hospital clinics, formerly associated with Glenn Medical Center, are also hoping to expand pediatric capacity.</li> <li>• The Enloe Health Gonzales Comprehensive Cancer Center in Chico recently held its ribbon cutting. The center intends to begin seeing patients the following month.</li> <li>• A federal bankruptcy court judge extended the timeline for Oroville Hospital’s restructuring and/or sale. The original round of bids did not satisfy the debtors, and the institution was not sold through that initial process. Hospital leadership is reportedly hoping that operational changes will allow the current system to continue functioning longer while the restructuring process proceeds. Additional news indicated that the hospital and its parent organization opened a lawsuit against the prior chief executive officer related to organizational challenges. Oroville Hospital is expected to remain in a difficult and uncertain situation for the near future.</li> <li>• In the five-county Chico region, current clinical-efficiency challenges appear clustered around hospital readmissions. The most prominent readmission diagnoses identified were diabetes and congestive heart failure. The region will work with hospitals, clinics, and potentially third parties to identify patients at risk for readmission. The goal of the effort is to determine how additional outpatient supports can be provided to keep patients stable in the outpatient setting and reduce avoidable readmissions.</li> </ul> |
| IV.E<br>Status Update,<br>Regional Medical | <p><b>Partnership’s Regional Medical Director for Glenn, Butte, Sutter, and Colusa Counties presented a brief update on activities on behalf of Siskiyou, Modoc, Shasta, Lassen, Trinity, and Tehama Counties.</b></p> <ul style="list-style-type: none"> <li>• Dr. Kirk, a Redding region OB/GYN, is transitioning from private practice to a hospital-based practice through the Mercy/St. Elizabeth system. Dr. Kirk is expected to continue seeing Partnership members in the new setting but appears likely to serve more in a hospitalist role while continuing to see Partnership patients.</li> <li>• The Redding Mercy cancer center is scheduled to open on Tuesday, August 18. The center is expected to support stabilization of oncology services, including both medical oncology and radiation oncology.</li> <li>• Partnership has been working closely with Shasta Regional Medical Center to expand outpatient radiology capacity in the Redding area.</li> <li>• Potential additional outpatient radiology access may include outpatient MRI, additional outpatient mammography, and possible DEXA scan availability.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IV.F<br>Status Update,<br>Regional Medical | <p><b>Partnership’s Regional Medical Director for Plumas, Sierra, Nevada, Yuba, and Placer Counties presented a brief update on activities.</b></p> <ul style="list-style-type: none"> <li>• Tahoe Forest in Nevada County is opening a mobile clinic for primary and urgent care as well as expanding those services in a new building. Dr. Brian Evans has stepped away from his role as CMO and Tahoe Forest to serve as Public Health Officer for Nevada County.</li> <li>• Partnership recently convened a Nevada County Enhanced Care Management Provider forum to facilitate network engagement and coordination.</li> <li>• Crisis stabilization unit temporarily closed during vendor transition but expected to reopen October 1, 2026.</li> <li>• Joint Leadership Initiative meetings are ongoing with area clinics in Placer County.</li> <li>• Partnered with <a href="#">Vision to Learn</a> in Lincoln to perform eye screenings and exams as well as provide glasses for more than 50 school-age children.</li> <li>• Placer County Health and Human Services received three national awards for recognition from the National Association of Counties, which recognizes innovative county government programs: <a href="#">The Harbor</a>, a 16-bed recovery unit designed to help bridge the gap for individuals that are waiting for residential substance abuse treatment; <a href="#">Eat Well</a>, an app connecting local businesses with excess food to low-income individuals, and Placer County Dashboard for coordinating local services across the county in real time.</li> <li>• All region counties received Partnership Expansion County Reinvestment Grants and will focus on well-care visits, immunizations, and prenatal care.</li> <li>• Partnership’s Chronic Disease Quality Measurements for Improvement team has been providing education to members regarding high blood pressure.</li> </ul>             |
| V. Old Business                            | No old business.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

| AGENDA ITEM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |               |                      |                        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------|------------------------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VI.A<br>Proposed 2027<br>Primary Care<br>Provider Quality<br>Incentive Program<br>(PCPQIP)<br>Measurement Set,<br>Continued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <div data-bbox="302 172 1035 228"> <p><b>Summary of Proposed Measure Changes for Measurement Year 2027</b></p> </div> <div data-bbox="302 261 726 289"> <p><b>(A) Core Measurement Set Measures</b></p> </div> <div data-bbox="302 293 1035 410"> <p>Providers have the potential to earn a total of 100 points in two measurement areas: Clinical Domain and Non-Clinical Domain. Individual measure values will be assigned to the final and approved measurement set.</p> </div> <div data-bbox="302 451 749 479"> <p><b>Changes to Existing Clinical Measures:</b></p> </div> <div data-bbox="302 483 1066 829"> <ul style="list-style-type: none"> <li>Chlamydia Screening (Clinical, All Practice Types) – Retire and make a monitoring measure with HEDIS criteria.</li> <li>Diabetes Management: Retinal Eye Exams (Clinical, Family Practice, and Internal Medicine) – Retire and make a monitoring measure. Maintaining this measure in a monitoring capacity supports early identification of care gaps, helps target interventions for high-risk members, and preserves visibility into an important clinical service without requiring it to drive formal stars scoring.</li> <li>Reducing Healthcare Disparity (Optional Clinical, All Practice Types) – Retire. DHCS changed approach for plan and expectations for reducing healthcare disparities.</li> </ul> </div> <div data-bbox="302 870 756 898"> <p><b><u>New Additions as Monitoring Measures</u></b></p> </div> <div data-bbox="302 906 394 933"> <p><b>Clinical</b></p> </div> <div data-bbox="302 938 1115 1179"> <ul style="list-style-type: none"> <li>Development Screening (Clinical, Family and Pediatric Practice)</li> <li>First Timely Prenatal Care Visit (Clinical, Family and Pediatric Practice)</li> <li>Adult Immunizations (Clinical, Family Practice, and Internal Medicine)</li> <li>Follow-up after Acute and Urgent Care Visits for Asthma (Clinical, All Practice Types)</li> <li>Asthma Medication Ratio (Clinical, All Practice Types)</li> </ul> </div> <div data-bbox="302 1182 451 1209"> <p><b>Non-Clinical</b></p> </div> <div data-bbox="302 1214 1207 1320"> <ul style="list-style-type: none"> <li>Tobacco Use Screening and Cessation (All Practice Types)</li> <li>Ambulatory Care Sensitive Admissions (Family Practice and Internal Medicine)</li> <li>Avoidable Emergency Department (ED) Visits (All Practice Types)</li> </ul> </div> <div data-bbox="1549 172 1606 199"> <p><b>Key:</b></p> </div> <div data-bbox="1249 212 1911 240"> <p>New Measure    Change to Measure Design    Measure removed</p> </div> <div data-bbox="1123 261 2039 1198"> <table> <tr> <th>2026 Measures</th><th>2027 Recommendations</th></tr> <tr> <td colspan="2"><b>Clinical Domain</b></td></tr> <tr> <td> <b>Family Medicine:</b> <ol style="list-style-type: none"> <li>Breast Cancer Screening (40-74yo)</li> <li>Cervical Cancer Screening</li> <li>Child and Adolescent Well Care Visits</li> <li>Childhood Immunization Status: Combo 10</li> <li>Colorectal Cancer Screening</li> <li>Comprehensive Diabetes Management: HbA1c Good Control</li> <li>Comprehensive Diabetes Management: Retinal Eye Exams</li> <li>Controlling High Blood Pressure</li> <li>Immunizations for Adolescents – Combo 2</li> <li>Well-Child Visits in the First 15 Months of Life</li> <li>Lead Screening in Children</li> <li>Chlamydia Screening (16-24yo)</li> <li>Kidney Health Evaluation for Patients with Diabetes</li> <li>Well-Child Visits in the first 15-30 months of life – <b>Monitoring</b></li> <li>Topical fluoride in Children – <b>Monitoring</b></li> <li>Reducing Healthcare Disparity (Participation is Optional)</li> </ol> </td><td> <b>Family Medicine:</b> <ol style="list-style-type: none"> <li>Breast Cancer Screening (40-74yo)</li> <li>Cervical Cancer Screening</li> <li>Child and Adolescent Well Care Visits</li> <li>Childhood Immunization Status: Combo 10</li> <li>Colorectal Cancer Screening</li> <li>Comprehensive Diabetes Management: HbA1c Good Control</li> <li><del>Comprehensive Diabetes Management: Retinal Eye Exams</del> – <b>Retire to Monitoring Status</b></li> <li>Controlling High Blood Pressure</li> <li>Immunizations for Adolescents – Combo 2</li> <li>Well-Child Visits in the First 15 Months of Life</li> <li>Lead Screening in Children</li> <li><del>Chlamydia Screening (16-24yo)</del> – <b>Retire to Monitoring Status</b></li> <li>Kidney Health Evaluation for Patients with Diabetes</li> <li>Well-Child Visits in the first 15-30 months of life – <b>Keep as Monitoring</b></li> <li>Topical fluoride in Children – <b>Keep as Monitoring</b></li> <li>Developmental Screening – <b>New Monitoring</b></li> <li>First Timely Prenatal Care Visit – <b>New Monitoring</b></li> <li>Adult Immunization – <b>New Monitoring</b></li> <li>Follow-up after Acute and Urgent Care Visits for Asthma – <b>New Monitoring</b></li> <li>Asthma Medication Ratio – <b>New Monitoring</b></li> </ol> </td></tr> <tr> <td></td><td> <ol style="list-style-type: none"> <li>Tobacco Use Screening and Cessation – <b>New Monitoring</b></li> <li><del>Reducing Healthcare Disparity (Participation is Optional)</del></li> </ol> </td></tr> </table> </div> | 2026 Measures | 2027 Recommendations | <b>Clinical Domain</b> |  | <b>Family Medicine:</b> <ol style="list-style-type: none"> <li>Breast Cancer Screening (40-74yo)</li> <li>Cervical Cancer Screening</li> <li>Child and Adolescent Well Care Visits</li> <li>Childhood Immunization Status: Combo 10</li> <li>Colorectal Cancer Screening</li> <li>Comprehensive Diabetes Management: HbA1c Good Control</li> <li>Comprehensive Diabetes Management: Retinal Eye Exams</li> <li>Controlling High Blood Pressure</li> <li>Immunizations for Adolescents – Combo 2</li> <li>Well-Child Visits in the First 15 Months of Life</li> <li>Lead Screening in Children</li> <li>Chlamydia Screening (16-24yo)</li> <li>Kidney Health Evaluation for Patients with Diabetes</li> <li>Well-Child Visits in the first 15-30 months of life – <b>Monitoring</b></li> <li>Topical fluoride in Children – <b>Monitoring</b></li> <li>Reducing Healthcare Disparity (Participation is Optional)</li> </ol> | <b>Family Medicine:</b> <ol style="list-style-type: none"> <li>Breast Cancer Screening (40-74yo)</li> <li>Cervical Cancer Screening</li> <li>Child and Adolescent Well Care Visits</li> <li>Childhood Immunization Status: Combo 10</li> <li>Colorectal Cancer Screening</li> <li>Comprehensive Diabetes Management: HbA1c Good Control</li> <li><del>Comprehensive Diabetes Management: Retinal Eye Exams</del> – <b>Retire to Monitoring Status</b></li> <li>Controlling High Blood Pressure</li> <li>Immunizations for Adolescents – Combo 2</li> <li>Well-Child Visits in the First 15 Months of Life</li> <li>Lead Screening in Children</li> <li><del>Chlamydia Screening (16-24yo)</del> – <b>Retire to Monitoring Status</b></li> <li>Kidney Health Evaluation for Patients with Diabetes</li> <li>Well-Child Visits in the first 15-30 months of life – <b>Keep as Monitoring</b></li> <li>Topical fluoride in Children – <b>Keep as Monitoring</b></li> <li>Developmental Screening – <b>New Monitoring</b></li> <li>First Timely Prenatal Care Visit – <b>New Monitoring</b></li> <li>Adult Immunization – <b>New Monitoring</b></li> <li>Follow-up after Acute and Urgent Care Visits for Asthma – <b>New Monitoring</b></li> <li>Asthma Medication Ratio – <b>New Monitoring</b></li> </ol> |  | <ol style="list-style-type: none"> <li>Tobacco Use Screening and Cessation – <b>New Monitoring</b></li> <li><del>Reducing Healthcare Disparity (Participation is Optional)</del></li> </ol> |
| 2026 Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2027 Recommendations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |               |                      |                        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                             |
| <b>Clinical Domain</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |               |                      |                        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                             |
| <b>Family Medicine:</b> <ol style="list-style-type: none"> <li>Breast Cancer Screening (40-74yo)</li> <li>Cervical Cancer Screening</li> <li>Child and Adolescent Well Care Visits</li> <li>Childhood Immunization Status: Combo 10</li> <li>Colorectal Cancer Screening</li> <li>Comprehensive Diabetes Management: HbA1c Good Control</li> <li>Comprehensive Diabetes Management: Retinal Eye Exams</li> <li>Controlling High Blood Pressure</li> <li>Immunizations for Adolescents – Combo 2</li> <li>Well-Child Visits in the First 15 Months of Life</li> <li>Lead Screening in Children</li> <li>Chlamydia Screening (16-24yo)</li> <li>Kidney Health Evaluation for Patients with Diabetes</li> <li>Well-Child Visits in the first 15-30 months of life – <b>Monitoring</b></li> <li>Topical fluoride in Children – <b>Monitoring</b></li> <li>Reducing Healthcare Disparity (Participation is Optional)</li> </ol> | <b>Family Medicine:</b> <ol style="list-style-type: none"> <li>Breast Cancer Screening (40-74yo)</li> <li>Cervical Cancer Screening</li> <li>Child and Adolescent Well Care Visits</li> <li>Childhood Immunization Status: Combo 10</li> <li>Colorectal Cancer Screening</li> <li>Comprehensive Diabetes Management: HbA1c Good Control</li> <li><del>Comprehensive Diabetes Management: Retinal Eye Exams</del> – <b>Retire to Monitoring Status</b></li> <li>Controlling High Blood Pressure</li> <li>Immunizations for Adolescents – Combo 2</li> <li>Well-Child Visits in the First 15 Months of Life</li> <li>Lead Screening in Children</li> <li><del>Chlamydia Screening (16-24yo)</del> – <b>Retire to Monitoring Status</b></li> <li>Kidney Health Evaluation for Patients with Diabetes</li> <li>Well-Child Visits in the first 15-30 months of life – <b>Keep as Monitoring</b></li> <li>Topical fluoride in Children – <b>Keep as Monitoring</b></li> <li>Developmental Screening – <b>New Monitoring</b></li> <li>First Timely Prenatal Care Visit – <b>New Monitoring</b></li> <li>Adult Immunization – <b>New Monitoring</b></li> <li>Follow-up after Acute and Urgent Care Visits for Asthma – <b>New Monitoring</b></li> <li>Asthma Medication Ratio – <b>New Monitoring</b></li> </ol>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |               |                      |                        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <ol style="list-style-type: none"> <li>Tobacco Use Screening and Cessation – <b>New Monitoring</b></li> <li><del>Reducing Healthcare Disparity (Participation is Optional)</del></li> </ol>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |               |                      |                        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                             |

| AGENDA ITEM                                                                                                                                                                                                           | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VI.A<br>Proposed 2027<br>Primary Care<br>Provider Quality<br>Incentive Program<br>(PCPQIP)<br>Measurement Set<br>Continued                                                                                            | Clinical Domain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Clinical Domain                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                       | Internal Medicine:<br>1. Breast Cancer Screening (40-74yo)<br>2. Cervical Cancer Screening<br>3. Colorectal Cancer Screening<br>4. Controlling High Blood Pressure<br>5. Comprehensive Diabetes Management: HbA1c Good Control<br>6. Comprehensive Diabetes Management: Retinal Eye Exams<br>7. Chlamydia Screening (21-24yo)<br>8. Reducing Healthcare Disparity (Participation is Optional)<br>9. Kidney Health Evaluation for Patients with Diabetes                                                                                                                                                                                                                                                 | Internal Medicine:<br>1. Breast Cancer Screening (40-74yo)<br>2. Cervical Cancer Screening<br>3. Colorectal Cancer Screening<br>4. Controlling High Blood Pressure<br>5. Comprehensive Diabetes Management: HbA1c Good Control<br>6. Comprehensive Diabetes Management: Retinal Eye Exams — Retire to Monitoring Status<br>7. Chlamydia Screening (21-24yo) — Retire to Monitoring Status<br>8. Kidney Health Evaluation for Patients with Diabetes<br>9. First Timely Prenatal Care Visit — New Monitoring<br>10. Adult Immunization — New Monitoring<br>11. Follow-up after Acute and Urgent Care Visits for Asthma — New Monitoring<br>12. Asthma Medication Ratio — New Monitoring<br>13. Tobacco Use Screening and Cessation — New Monitoring<br>14. Reducing Healthcare Disparity (Participation is Optional) | Pediatric Medicine:<br>1. Child and Adolescent Well Care Visits<br>2. Childhood Immunization Status: Combo 10<br>3. Immunizations for Adolescents – Combo 2<br>4. Well-Child Visits in the First 15 Months of Life<br><br>6. Well-Child Visits in the first 15-30 months of life<br>7. Chlamydia Screening (16-20yo)<br>8. Topical fluoride in Children – Monitoring<br>9. Reducing Healthcare Disparity (Participation is Optional) | Pediatric Medicine:<br>1. Child and Adolescent Well Care Visits<br>2. Childhood Immunization Status: Combo 10<br>3. Immunizations for Adolescents – Combo 2<br>4. Well-Child Visits in the First 15 Months of Life<br><br>6. Well-Child Visits in the first 15-30 months of life<br>7. Chlamydia Screening (16-20yo) — Retire to Monitoring Status<br>8. Topical fluoride in Children – Keep as Monitoring<br>9. Developmental Screening — New Monitoring<br>10. Follow-up after Acute and Urgent Care Visits for Asthma — New Monitoring<br>11. Asthma Medication Ratio — New Monitoring<br>12. Tobacco Use Screening and Cessation — New Monitoring<br>13. Reducing Healthcare Disparity (Participation is Optional) |
|                                                                                                                                                                                                                       | <b>Changes to Existing Non-Clinical Measures</b> <ul style="list-style-type: none"><li>• Patient Experience (Non-Clinical) – Redesign to Consumer Assessment of Healthcare Providers and Systems (CAHPS) measure requirements, includes a robust improvement plan and ongoing monthly reporting. The two composite measures for the CG-CAHPS survey are access and communication, which are key drivers to patient satisfaction.</li><li>• Ambulatory Care Sensitive Admissions (Family Practice and Internal Medicine) – Measure name change for reporting purposes.</li><li>• Avoidable Emergency Department (ED) Visits (All Practice Types) – Measure name change for reporting purposes.</li></ul> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                       | 2026 Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2027 Recommendations                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Non-Clinical Domain                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Family Medicine & Internal Medicine:<br>1. Ambulatory Care Sensitive Admissions<br>2. Follow-up within 7 days after Hospital Discharge<br><br>3. Avoidable ED Visits<br>4. PCP Office Visits<br>5. Patient Experience |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Family Medicine & Internal Medicine:<br>1. Potentially Preventable Admissions<br>2. Follow-up within 7 days after Hospital Discharge<br><br>3. Low-Acuity Non-Emergent ED Visits<br>4. PCP Office Visits<br>5. Patient Experience                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Non-Clinical Domain                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Pediatric Medicine:<br>1. Avoidable ED Visits<br>2. PCP Office Visits<br>3. Patient Experience                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pediatric Medicine:<br>1. Low-Acuity Non-Emergent ED Visits<br>2. PCP Office Visits<br>3. Patient Experience                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

| AGENDA ITEM                                                                                                                                                                                                                                                                                                                                                                                                   | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                 |  |                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VI.A<br>Proposed 2027<br>Primary Care<br>Provider Quality<br>Incentive Program<br>(PCPQIP)<br>Measurement Set,<br>Continued                                                                                                                                                                                                                                                                                   | <div data-bbox="304 180 1081 665"> <p><b>Unit of Service Measures</b></p> <p><b>Providers receive payment for each unit of service they provide.</b></p> <p><u>Changes to Existing Unit of Service Measures:</u></p> <ul style="list-style-type: none"> <li>Tobacco Use Screening – Retire and make monitoring measure which adopts HEDIS criteria. Newly added MY2026 HEDIS measure includes both adolescents (12 years of age and older) and adults along with a requirement for cessation intervention.</li> <li>ECDS – Retire. * No uploads will be allowed for the following core clinical measures: BCS, CCS, COL, LSC, IMA, and CIS10. NCQA and MCAS measures will be transitioning to ECDS reporting only (i.e., no manual uploads will be permitted) by 2029. This data exchange from the provider’s Electronic Health Records to Datalink (a qualified HEDIS data aggregator), allows Partnership to capture clinical screenings, immunization records, follow-up care, and outcomes.</li> </ul> </div> <div data-bbox="304 706 1018 738"> <p><i>Proposed measurement set was approved by PAC voting members.</i></p> </div> <div data-bbox="1113 191 2043 565"> <table> <tr> <th colspan="2">Unit of Service</th></tr> <tr> <td> <b>All Sites:</b> <ol style="list-style-type: none"> <li>Clinician Education on Improving Medication Management</li> <li>Advance Care Planning</li> <li>Extended Office Hours</li> <li>PCMH Certification</li> <li>Peer-led and Pediatric Group Visits</li> <li>Health Information Exchange</li> <li>Health Equity</li> <li>Tobacco Use Screening</li> <li>Electronic Clinical Data Systems (ECDS)</li> </ol> </td><td> <b>All Sites:</b> <ol style="list-style-type: none"> <li>Clinician Education on Improving Medication Management</li> <li>Advance Care Planning</li> <li>Extended Office Hours</li> <li>PCMH Certification</li> <li>Peer-led and Pediatric Group Visits</li> <li>Health Information Exchange</li> <li>Health Equity</li> <li><del>Tobacco Use Screening – Retire</del></li> <li><del>Electronic Clinical Data Systems (ECDS) – Retire</del></li> </ol> </td></tr> </table> </div> | Unit of Service |  | <b>All Sites:</b> <ol style="list-style-type: none"> <li>Clinician Education on Improving Medication Management</li> <li>Advance Care Planning</li> <li>Extended Office Hours</li> <li>PCMH Certification</li> <li>Peer-led and Pediatric Group Visits</li> <li>Health Information Exchange</li> <li>Health Equity</li> <li>Tobacco Use Screening</li> <li>Electronic Clinical Data Systems (ECDS)</li> </ol> | <b>All Sites:</b> <ol style="list-style-type: none"> <li>Clinician Education on Improving Medication Management</li> <li>Advance Care Planning</li> <li>Extended Office Hours</li> <li>PCMH Certification</li> <li>Peer-led and Pediatric Group Visits</li> <li>Health Information Exchange</li> <li>Health Equity</li> <li><del>Tobacco Use Screening – Retire</del></li> <li><del>Electronic Clinical Data Systems (ECDS) – Retire</del></li> </ol> |
| Unit of Service                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                 |  |                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>All Sites:</b> <ol style="list-style-type: none"> <li>Clinician Education on Improving Medication Management</li> <li>Advance Care Planning</li> <li>Extended Office Hours</li> <li>PCMH Certification</li> <li>Peer-led and Pediatric Group Visits</li> <li>Health Information Exchange</li> <li>Health Equity</li> <li>Tobacco Use Screening</li> <li>Electronic Clinical Data Systems (ECDS)</li> </ol> | <b>All Sites:</b> <ol style="list-style-type: none"> <li>Clinician Education on Improving Medication Management</li> <li>Advance Care Planning</li> <li>Extended Office Hours</li> <li>PCMH Certification</li> <li>Peer-led and Pediatric Group Visits</li> <li>Health Information Exchange</li> <li>Health Equity</li> <li><del>Tobacco Use Screening – Retire</del></li> <li><del>Electronic Clinical Data Systems (ECDS) – Retire</del></li> </ol>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                 |  |                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| VI.B<br>Healthcare<br>Effectiveness Data<br>Information Set<br>(HEDIS ®) Annual<br>Summary of<br>Performance                                                                                                                                                                                                                                                                                                  | <p><b>Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                 |  |                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

| AGENDA ITEM                                                                                   | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                    |                                                                       |                                                                                                                    |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------|-----------------------------------------|------------------------|--------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------|-----------|--------------------|-----------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------|--------|------------|----------------------------------------------------|--------------------------------------------|-------------------|--------|-----------------|------------------------------|------------------------------------------------------------------------|----------------------|-----------|------|------|-----|-------------------------|-----------|------|------|-----|
| VI.B<br>Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance | <p><b>Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance</b></p> <p>Presentation reviewed Partnership’s results in the context of DHCS accountability programs, including the measures and performance expectations DHCS uses to prioritize member health and clinical care statewide. The goal is to help provider organizations understand what is most important from a performance and accountability standpoint and to support local priority-setting.</p> <p><b>Partnership’s Quality Accountability Programs</b></p> <ul style="list-style-type: none"><li>• DHCS has rolled out a number of additional accountability programs that look at HEDIS performance and have financial consequences for the plan.</li><li>• Overview is very high level because the programs are complex. Regional and county measure rates are growing in importance and Partnership is focused on the regional priorities and goals seen as the best path towards high performance in all programs.</li><li>• Partnership has between \$70-80M in financial risk annually in DHCS accountability programs.</li><li>• <b>Quality Withholds and Incentives:</b> subset of MCAS measures, dollars of income withheld and earned back by high performance OR year-over-year significant improvement on measures at the Quality Rating Region level.</li><li>• <b>Clinical Efficiencies:</b> Penalizes plan for high inpatient utilization, one key driver is unmanaged complex chronic conditions.</li><li>• <b>Community Reinvestments for Quality:</b> looks at MCAS performance at the County level, additional percentage of Partnership’s profit given to counties with multiple measures in any measure domain below 50th</li><li>• <b>Sanctions:</b> our original accountability program, any MCAS measure &lt; 50th</li><li>• <b>Quality Factor Score:</b> our composite performance rate compared to other California Managed Care Plans (MCP).</li></ul> <table><tr><th>Program</th><th>Geographic Impact</th><th>Financial Impact</th><th>Low Performance Trigger</th><th>Path to High Performance</th></tr><tr><td>Quality Withholds and Incentive Program</td><td>Quality Rating Regions</td><td>\$Tens of Millions</td><td>&lt;67th percentile performance AND &lt;25% YoY improvement</td><td>North Bay Area: <b>Achievement</b><br/>Rural Upper North and Rural Upper Central: <b>Year-over year improvement</b></td></tr><tr><td>Clinical Efficiencies</td><td>Plan Wide</td><td>\$Tens of Millions</td><td>High inpatient utilization by members with complex chronic conditions</td><td><b>Intensive case management of high-risk members</b></td></tr><tr><td>Community Reinvestments - Quality</td><td>County</td><td>\$Millions</td><td>2+ measures &lt;50th percentile in any measure domain</td><td>County-level <b>measure prioritization</b></td></tr><tr><td>Quality Sanctions</td><td>County</td><td>\$100k - \$500k</td><td>&lt;50th percentile performance</td><td><b>Data completeness, impact of high performance in other programs</b></td></tr><tr><td>Quality Factor Score</td><td>Plan Wide</td><td>None</td><td>None</td><td>n/a</td></tr><tr><td>NCQA Health Plan Rating</td><td>Plan Wide</td><td>None</td><td>None</td><td>n/a</td></tr></table> | Program            | Geographic Impact                                                     | Financial Impact                                                                                                   | Low Performance Trigger | Path to High Performance | Quality Withholds and Incentive Program | Quality Rating Regions | \$Tens of Millions | <67th percentile performance AND <25% YoY improvement | North Bay Area: <b>Achievement</b><br>Rural Upper North and Rural Upper Central: <b>Year-over year improvement</b> | Clinical Efficiencies | Plan Wide | \$Tens of Millions | High inpatient utilization by members with complex chronic conditions | <b>Intensive case management of high-risk members</b> | Community Reinvestments - Quality | County | \$Millions | 2+ measures <50th percentile in any measure domain | County-level <b>measure prioritization</b> | Quality Sanctions | County | \$100k - \$500k | <50th percentile performance | <b>Data completeness, impact of high performance in other programs</b> | Quality Factor Score | Plan Wide | None | None | n/a | NCQA Health Plan Rating | Plan Wide | None | None | n/a |
| Program                                                                                       | Geographic Impact                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Financial Impact   | Low Performance Trigger                                               | Path to High Performance                                                                                           |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
| Quality Withholds and Incentive Program                                                       | Quality Rating Regions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | \$Tens of Millions | <67th percentile performance AND <25% YoY improvement                 | North Bay Area: <b>Achievement</b><br>Rural Upper North and Rural Upper Central: <b>Year-over year improvement</b> |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
| Clinical Efficiencies                                                                         | Plan Wide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | \$Tens of Millions | High inpatient utilization by members with complex chronic conditions | <b>Intensive case management of high-risk members</b>                                                              |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
| Community Reinvestments - Quality                                                             | County                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | \$Millions         | 2+ measures <50th percentile in any measure domain                    | County-level <b>measure prioritization</b>                                                                         |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
| Quality Sanctions                                                                             | County                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | \$100k - \$500k    | <50th percentile performance                                          | <b>Data completeness, impact of high performance in other programs</b>                                             |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
| Quality Factor Score                                                                          | Plan Wide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | None               | None                                                                  | n/a                                                                                                                |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |
| NCQA Health Plan Rating                                                                       | Plan Wide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | None               | None                                                                  | n/a                                                                                                                |                         |                          |                                         |                        |                    |                                                       |                                                                                                                    |                       |           |                    |                                                                       |                                                       |                                   |        |            |                                                    |                                            |                   |        |                 |                              |                                                                        |                      |           |      |      |     |                         |           |      |      |     |

| AGENDA ITEM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------|---------|--|-------------------|--------|---------------------------------------|--------|----------------------------------------|-----------|-----|--------------------------------------------------|-------|----------------------------------|-----|-----------------------------------|-------|----------------------------------------|-----|----------------------------|--------|-------------------------------|-------|-----------------------------------------|-------|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--------|---------|--|-----------------|-----|-----------------------------------------------|-----|------------------------------|-----|-------------------------|---------------------------------|-------|-------------------------|-------|---------------------------|-----|---------------------|---------|--------------------------------------|----------|--------------------------|
| VI.B Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <b>Managed Care Accountability Set (MCAS) Results</b><br><b>Accountable Measures for MY2025</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <ul style="list-style-type: none"><li>18 measures in MY2025</li><li>All 18 measures from MY2024 continue in MY2025</li><li>Accountable measures must meet or exceed the Minimum Performance Level (MPL) (i.e. 50th percentile national Medicaid percentile) to avoid sanctions</li><li>Quality Withhold Measures must show significant year-over-year improvement or exceed 67th percentile for full points</li><li>Community Reinvestment additional 5% triggered by 1+ measure &lt; MPL in each measure domain</li></ul>                                                                                                                                                                                                                                                                                                                   |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <table><tr><th>Domain</th><th colspan="2">Measure</th></tr><tr><td rowspan="2">Behavioral Health</td><td>FUA-30</td><td>F-Up after ED Visit for Substance Use</td></tr><tr><td>FUM-30</td><td>F-Up after ED Visit for Mental Illness</td></tr><tr><td rowspan="8">Pediatric</td><td>WCV</td><td><b>Child &amp; Adolescent Well Care Visits**</b></td></tr><tr><td>CIS-E</td><td><b>Childhood Immunizations**</b></td></tr><tr><td>DEV</td><td>Developmental Screening in 0-3yrs</td></tr><tr><td>IMA-E</td><td><b>Immunizations for Adolescents**</b></td></tr><tr><td>LSC</td><td>Lead Screening in Children</td></tr><tr><td>TFL-CH</td><td>Topical Fluoride for Children</td></tr><tr><td>W30+6</td><td><b>Well Child Visits: 0-15 Months**</b></td></tr><tr><td>W30+2</td><td><b>Well Child Visits: 15-30 Months**</b></td></tr></table> |                                               | Domain                                           | Measure |  | Behavioral Health | FUA-30 | F-Up after ED Visit for Substance Use | FUM-30 | F-Up after ED Visit for Mental Illness | Pediatric | WCV | <b>Child &amp; Adolescent Well Care Visits**</b> | CIS-E | <b>Childhood Immunizations**</b> | DEV | Developmental Screening in 0-3yrs | IMA-E | <b>Immunizations for Adolescents**</b> | LSC | Lead Screening in Children | TFL-CH | Topical Fluoride for Children | W30+6 | <b>Well Child Visits: 0-15 Months**</b> | W30+2 | <b>Well Child Visits: 15-30 Months**</b> | <table><tr><th>Domain</th><th colspan="2">Measure</th></tr><tr><td rowspan="3">Chronic Disease</td><td>GSD</td><td><b>Hemoglobin A1c Poor Control (&gt;9%)**</b></td></tr><tr><td>CBP</td><td><b>Controlling High BP**</b></td></tr><tr><td>AMR</td><td>Asthma Medication Ratio</td></tr><tr><td rowspan="5">Reproductive /Cancer Prevention</td><td>BCS-E</td><td>Breast Cancer Screening</td></tr><tr><td>CCS-E</td><td>Cervical Cancer Screening</td></tr><tr><td>CHL</td><td>Chlamydia Screening</td></tr><tr><td>PPC-Pre</td><td><b>Timeliness of Prenatal Care**</b></td></tr><tr><td>PPC-Post</td><td><b>Postpartum Care**</b></td></tr></table> |  |  | Domain | Measure |  | Chronic Disease | GSD | <b>Hemoglobin A1c Poor Control (&gt;9%)**</b> | CBP | <b>Controlling High BP**</b> | AMR | Asthma Medication Ratio | Reproductive /Cancer Prevention | BCS-E | Breast Cancer Screening | CCS-E | Cervical Cancer Screening | CHL | Chlamydia Screening | PPC-Pre | <b>Timeliness of Prenatal Care**</b> | PPC-Post | <b>Postpartum Care**</b> |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Domain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Measure                                       |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Behavioral Health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | FUA-30                                        | F-Up after ED Visit for Substance Use            |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | FUM-30                                        | F-Up after ED Visit for Mental Illness           |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Pediatric                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | WCV                                           | <b>Child &amp; Adolescent Well Care Visits**</b> |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CIS-E                                         | <b>Childhood Immunizations**</b>                 |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | DEV                                           | Developmental Screening in 0-3yrs                |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | IMA-E                                         | <b>Immunizations for Adolescents**</b>           |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| LSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Lead Screening in Children                    |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| TFL-CH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Topical Fluoride for Children                 |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| W30+6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <b>Well Child Visits: 0-15 Months**</b>       |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| W30+2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <b>Well Child Visits: 15-30 Months**</b>      |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| Domain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Measure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| Chronic Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | GSD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>Hemoglobin A1c Poor Control (&gt;9%)**</b> |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | CBP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>Controlling High BP**</b>                  |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | AMR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Asthma Medication Ratio                       |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| Reproductive /Cancer Prevention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | BCS-E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Breast Cancer Screening                       |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | CCS-E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Cervical Cancer Screening                     |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | CHL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Chlamydia Screening                           |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PPC-Pre                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <b>Timeliness of Prenatal Care**</b>          |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PPC-Post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <b>Postpartum Care**</b>                      |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| <b>** Designates a Quality Withhold measure</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| <b>Accountability Programs Emphasize Local Performance</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |
| <ul style="list-style-type: none"><li>Path to high performance on DHCS accountability programs is through county and regional measure rate improvement</li><li>North Bay Area (Fairfield &amp; Santa Rosa): sustaining high achievement<ul style="list-style-type: none"><li>&gt;67th percentile on all MCAS measures</li></ul></li><li>Rural Upper North (Redding and Eureka) and Rural Upper Central (Auburn and Chico): continuous improvement on prioritized measures<ul style="list-style-type: none"><li>Rural North: Moving towards 67th percentile on Withhold measures</li><li>Rural Central: Moving towards 50th percentile on Withhold measures</li></ul></li></ul> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                               |                                                  |         |  |                   |        |                                       |        |                                        |           |     |                                                  |       |                                  |     |                                   |       |                                        |     |                            |        |                               |       |                                         |       |                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |  |        |         |  |                 |     |                                               |     |                              |     |                         |                                 |       |                         |       |                           |     |                     |         |                                      |          |                          |

| AGENDA ITEM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|------------------------------------------|---------------------------------|----|---------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------|--------|---------------------------------|---|---------------------------------------------------|--------|-----------------------------------------------------------|--------|----------------------------------------------------------------|--------|----------------------------------------------------------|--------|----------------------------------|--------|----------------------------------------------|--------|-----------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------------|-------------------------------|--|-------------------------------|--------|------------------------------------------|--------|------------------------------------------------------------------------|--------|---------------------------------------------------------|--|---------------------------------|--------|-----------------------------------|--------|------------------------------------|--------|-------------------------------------------------------------|--------|------------------------------------------------------------------------|--------|
| VI.B Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | <b>MY2025 Plan-Wide MCAS Performance</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Twelve measures met or exceeded the minimum performance level or the > 50th percentile, one at 90th (PPC), five at 75 <sup>th</sup> , six measures < 50 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <table><thead><tr><th>Measure</th><th>MY2025 RATE</th></tr></thead><tbody><tr><td colspan="2"><b>Behavioral Health Domain</b></td></tr><tr><td>Follow-Up After Emergency Department Visit for Substance Use - 30-Days (FUA-30)</td><td>41.35%</td></tr><tr><td>Follow-Up After Emergency Department Visit for Mental Illness - 30-Days (FUM-30)</td><td>50.26%</td></tr><tr><td colspan="2"><b>Children's Health Domain</b></td></tr><tr><td>Child and Adolescent Well-Care Visits (WCV) **</td><td>52.57%</td></tr><tr><td>Childhood Immunization Status - Combination 10 (CIS-E) **</td><td>26.74%</td></tr><tr><td>Developmental Screening in the First Three Years of Life (DEV)</td><td>39.42%</td></tr><tr><td>Immunizations for Adolescents - Combination 2 (IMA-E) **</td><td>39.39%</td></tr><tr><td>Lead Screening in Children (LSC)</td><td>74.94%</td></tr><tr><td>Topical Fluoride for Children (TFL)</td><td>21.07%</td></tr><tr><td>Well-Child Visits in the First 30 Months of Life - 2+ visits in 15-30 months (W30-2) **</td><td>76.64%</td></tr><tr><td>Well-Child Visits in the First 30 Months of Life - 6+ visits in 0-15 months (W30-6) **</td><td>64.64%</td></tr></tbody></table> | Measure                   | MY2025 RATE                              | <b>Behavioral Health Domain</b> |    | Follow-Up After Emergency Department Visit for Substance Use - 30-Days (FUA-30) | 41.35% | Follow-Up After Emergency Department Visit for Mental Illness - 30-Days (FUM-30) | 50.26% | <b>Children's Health Domain</b> |   | Child and Adolescent Well-Care Visits (WCV) **    | 52.57% | Childhood Immunization Status - Combination 10 (CIS-E) ** | 26.74% | Developmental Screening in the First Three Years of Life (DEV) | 39.42% | Immunizations for Adolescents - Combination 2 (IMA-E) ** | 39.39% | Lead Screening in Children (LSC) | 74.94% | Topical Fluoride for Children (TFL)          | 21.07% | Well-Child Visits in the First 30 Months of Life - 2+ visits in 15-30 months (W30-2) ** | 76.64% | Well-Child Visits in the First 30 Months of Life - 6+ visits in 0-15 months (W30-6) ** | 64.64% | <table><thead><tr><th>Measure</th><th>MY2025 RATE</th></tr></thead><tbody><tr><td colspan="2"><b>Chronic Disease Domain</b></td></tr><tr><td>Asthma Medication Ratio (AMR)</td><td>73.33%</td></tr><tr><td>Controlling High Blood Pressure (CBP) **</td><td>67.40%</td></tr><tr><td>Glycemic Status Assessment for Patients With Diabetes (&gt;9%) (GSD) ** ^</td><td>27.74%</td></tr><tr><td colspan="2"><b>Reproductive Health and Cancer Prevention Domain</b></td></tr><tr><td>Breast Cancer Screening (BCS-E)</td><td>53.43%</td></tr><tr><td>Cervical Cancer Screening (CCS-E)</td><td>48.08%</td></tr><tr><td>Chlamydia Screening in Women (CHL)</td><td>58.98%</td></tr><tr><td>Prenatal and Postpartum Care: Postpartum Care (PPC-Post) **</td><td>90.02%</td></tr><tr><td>Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC-Pre) **</td><td>87.10%</td></tr></tbody></table> | Measure | MY2025 RATE | <b>Chronic Disease Domain</b> |  | Asthma Medication Ratio (AMR) | 73.33% | Controlling High Blood Pressure (CBP) ** | 67.40% | Glycemic Status Assessment for Patients With Diabetes (>9%) (GSD) ** ^ | 27.74% | <b>Reproductive Health and Cancer Prevention Domain</b> |  | Breast Cancer Screening (BCS-E) | 53.43% | Cervical Cancer Screening (CCS-E) | 48.08% | Chlamydia Screening in Women (CHL) | 58.98% | Prenatal and Postpartum Care: Postpartum Care (PPC-Post) ** | 90.02% | Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC-Pre) ** | 87.10% |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Measure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | MY2025 RATE               |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <b>Behavioral Health Domain</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Follow-Up After Emergency Department Visit for Substance Use - 30-Days (FUA-30)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 41.35%                    |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Follow-Up After Emergency Department Visit for Mental Illness - 30-Days (FUM-30)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 50.26%                    |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <b>Children's Health Domain</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Child and Adolescent Well-Care Visits (WCV) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 52.57%                    |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Childhood Immunization Status - Combination 10 (CIS-E) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 26.74%                    |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Developmental Screening in the First Three Years of Life (DEV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 39.42%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Immunizations for Adolescents - Combination 2 (IMA-E) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 39.39%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Lead Screening in Children (LSC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 74.94%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Topical Fluoride for Children (TFL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21.07%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Well-Child Visits in the First 30 Months of Life - 2+ visits in 15-30 months (W30-2) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 76.64%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Well-Child Visits in the First 30 Months of Life - 6+ visits in 0-15 months (W30-6) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 64.64%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Measure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | MY2025 RATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <b>Chronic Disease Domain</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Asthma Medication Ratio (AMR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 73.33%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Controlling High Blood Pressure (CBP) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 67.40%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Glycemic Status Assessment for Patients With Diabetes (>9%) (GSD) ** ^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27.74%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <b>Reproductive Health and Cancer Prevention Domain</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Breast Cancer Screening (BCS-E)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 53.43%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Cervical Cancer Screening (CCS-E)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 48.08%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Chlamydia Screening in Women (CHL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 58.98%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Prenatal and Postpartum Care: Postpartum Care (PPC-Post) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 90.02%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC-Pre) **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 87.10%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <div><div><div>Benchmark</div><div>90<sup>th</sup></div><div>67<sup>th</sup> or 75<sup>th</sup></div><div>50<sup>th</sup> – MPL or &gt;50<sup>th</sup> (CMS)</div><div>25<sup>th</sup> or 33<sup>rd</sup></div><div>&lt;25<sup>th</sup> or &lt;50<sup>th</sup> (CMS)</div></div><div></div></div>                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <div><div>** Quality Withhold measure</div><div>^ Inverse measure, lower rate is better</div></div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <b>MCAS Composite Score, MY2023 – MY2025</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <ul style="list-style-type: none"><li>Composite score represents Partnership’s aggregated performance on all 18 MCAS measures (measure benchmarks met in points / highest possible benchmarks in points)</li><li>Preliminary version of DHCS Quality Factor Score, published in Fall 2026</li></ul>                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <div><div><div>MY2023-MY2025 Composite Score, Plan-Wide</div><div></div><div><div>Plan-Wide Composite Score, 18 MCAS measures</div><div>All Measures at P50</div><div>DHCS MCP Aggregate Score</div></div></div></div>                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <table><thead><tr><th>Quality Compass Benchmark</th><th>Points Awarded per Measure's Performance</th></tr></thead><tbody><tr><td>90<sup>th</sup></td><td>10</td></tr><tr><td>82.5<sup>th</sup></td><td>9</td></tr><tr><td>75<sup>th</sup></td><td>8</td></tr><tr><td>62.5<sup>th</sup></td><td>7</td></tr><tr><td>50<sup>th</sup> – MPL or &gt;50<sup>th</sup> (CMS)</td><td>6</td></tr><tr><td>37.5<sup>th</sup></td><td>5</td></tr><tr><td>25<sup>th</sup></td><td>4</td></tr><tr><td>17.5<sup>th</sup></td><td>3</td></tr><tr><td>10<sup>th</sup></td><td>2</td></tr><tr><td>&lt;10<sup>th</sup> or &lt;50<sup>th</sup> (CMS)</td><td>1</td></tr></tbody></table> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Quality Compass Benchmark | Points Awarded per Measure's Performance | 90 <sup>th</sup>                | 10 | 82.5 <sup>th</sup>                                                              | 9      | 75 <sup>th</sup>                                                                 | 8      | 62.5 <sup>th</sup>              | 7 | 50 <sup>th</sup> – MPL or >50 <sup>th</sup> (CMS) | 6      | 37.5 <sup>th</sup>                                        | 5      | 25 <sup>th</sup>                                               | 4      | 17.5 <sup>th</sup>                                       | 3      | 10 <sup>th</sup>                 | 2      | <10 <sup>th</sup> or <50 <sup>th</sup> (CMS) | 1      |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| Quality Compass Benchmark                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Points Awarded per Measure's Performance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 90 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 82.5 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 75 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 62.5 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 50 <sup>th</sup> – MPL or >50 <sup>th</sup> (CMS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 37.5 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 25 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 17.5 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| 10 <sup>th</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |
| <10 <sup>th</sup> or <50 <sup>th</sup> (CMS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                           |                                          |                                 |    |                                                                                 |        |                                                                                  |        |                                 |   |                                                   |        |                                                           |        |                                                                |        |                                                          |        |                                  |        |                                              |        |                                                                                         |        |                                                                                        |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |         |             |                               |  |                               |        |                                          |        |                                                                        |        |                                                         |  |                                 |        |                                   |        |                                    |        |                                                             |        |                                                                        |        |


| AGENDA ITEM                                                                                | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |                              |        |                                   |        |                                   |        |                                                   |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------------------|--------|-----------------------------------|--------|-----------------------------------|--------|---------------------------------------------------|--|-----------|--------|--------------------------|--------|--------|--------|--------|--------|--------|------------------------------------------------------------------|-------|-------------|-------|------|------|-------|-------|-------|------------------|----------------------------------|------|-------------|------|------|------|------|------|------|--------------------------------------|---------------------------------------|-------|--------------|-------|------|------|------|-------|-------|---------------------------------------------------|-----------------------------------|---------------|--------------|---------------|------|----------------|-------|---------------|------|--------------------------------------|---------------------|-----------|--|------------------------------|--|-----------------------------------|--|---------------------------------|--|-----------|--------|--------------------------|--------|--------|--------|--------|--------|--------|----------------------------------------------------------------------------------|-------|---------------|-------|-------|-------|-------|-------|------|------------------|---------------------------------|------|-------------|------|------|-------|-------|------|-------|--------------------------------------|
| VI.B Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance | <div>MCAS Performance: Regional Opportunities</div> <div>Table shows additional MCAS measures that have opportunities for improvement: Development Screening in the 1st three years of life (DEV), Lead Screening in Children (LSC), Topical Fluoride for Children (TFL): we encourage providers to focus on access for well child visits, which is a priority and is a driver here, AND include the required screenings and referrals in these visits.</div> <div>Cervical Cancer Screening (CCS-E): transitioned to an ECDS measure in MY2025, so rates went down in some, though not all regions. This as an opportunity for Northbay Area to bring their rates up and pilot some new innovations such as self-swab testing to scale throughout the network.</div> <div><table><tr><th rowspan="2">Measure Description</th><th colspan="2">Plan-Wide</th><th colspan="2">North Bay Area Rating Region</th><th colspan="2">Rural Upper Central Rating Region</th><th colspan="2">Rural Upper North Rating Region</th><th rowspan="2">Benchmark</th></tr><tr><th>MY2024</th><th>MY2025 YoY points change</th><th>MY2024</th><th>MY2025</th><th>MY2024</th><th>MY2025</th><th>MY2024</th><th>MY2025</th></tr><tr><td>Developmental Screening in the First Three Years of Life (DEV) ^</td><td>&lt;50th</td><td>50th +9.77%</td><td>&lt;50th</td><td>50th</td><td>50th</td><td>&lt;50th</td><td>&lt;50th</td><td>&lt;50th</td><td>90<sup>th</sup></td></tr><tr><td>Lead Screening in Children (LSC)</td><td>75th</td><td>67th +3.16%</td><td>50th</td><td>50th</td><td>50th</td><td>33rd</td><td>75th</td><td>67th</td><td>87<sup>th</sup> or 75<sup>th</sup></td></tr><tr><td>Topical Fluoride for Children (TFL) ^</td><td>&lt;50th</td><td>&lt;50th +8.67%</td><td>&lt;50th</td><td>50th</td><td>50th</td><td>50th</td><td>&lt;50th</td><td>&lt;50th</td><td>50<sup>th</sup> – MPL or &gt;50<sup>th</sup> (CMS)</td></tr><tr><td>Cervical Cancer Screening (CCS-E)</td><td>50th (Hybrid)</td><td>25th -11.04%</td><td>75th (Hybrid)</td><td>50th</td><td>&lt;25th (Hybrid)</td><td>&lt;25th</td><td>25th (Hybrid)</td><td>50th</td><td>25<sup>th</sup> or 33<sup>rd</sup></td></tr></table><div><div>^ CMS measure, 50<sup>th</sup> percentile is highest benchmark</div><div>Improvement opportunity</div></div></div> <div>MCAS Performance: Data Completeness/Measure Limitations</div> <div>There were two measures with data completeness and measure limitation issues:</div> <div><div>Follow-Up After Emergency Department Visit for Mental Illness (FUM): though improved over 20 points, Partnership still falls under the 25th percentile. The measure definition changed and expanded the services counted towards the numerator, benefiting Partnership. Data completeness issues around this measure and are actively working on alternative data sources in MY2026</div><div>Breast Cancer Screening (BCS): This is an example of a measure limitation: age range expanded to 40-75 years, but benchmark was created for 50-75 year age range, so we’re applying an inappropriate benchmark to this year’s rate. We’ve advocated with DHCS for a workaround to this or to not hold the measure accountable.</div></div> <div>Significant Data Completeness and Measure Limitation Issues</div> <div>DHCS: No sanctions on FUM-30 or BCS-E in MY2025</div> <div><table><tr><th rowspan="2">Measure Description</th><th colspan="2">Plan-Wide</th><th colspan="2">North Bay Area Rating Region</th><th colspan="2">Rural Upper Central Rating Region</th><th colspan="2">Rural Upper North Rating Region</th><th rowspan="2">Benchmark</th></tr><tr><th>MY2024</th><th>MY2025 YoY points change</th><th>MY2024</th><th>MY2025</th><th>MY2024</th><th>MY2025</th><th>MY2024</th><th>MY2025</th></tr><tr><td>Follow-Up After Emergency Department Visit for Mental Illness - 30-Days (FUM-30)</td><td>&lt;25th</td><td>&lt;25th +21.25%</td><td>&lt;25th</td><td>&lt;25th</td><td>&lt;25th</td><td>&lt;25th</td><td>&lt;25th</td><td>33rd</td><td>90<sup>th</sup></td></tr><tr><td>Breast Cancer Screening (BCS-E)</td><td>50th</td><td>33rd -2.86%</td><td>50th</td><td>50th</td><td>&lt;25th</td><td>&lt;25th</td><td>25th</td><td>&lt;25th</td><td>87<sup>th</sup> or 75<sup>th</sup></td></tr></table><div><div>50<sup>th</sup> – MPL or &gt;50<sup>th</sup> (CMS)</div><div>25<sup>th</sup> or 33<sup>rd</sup></div><div>&lt;25<sup>th</sup> or &lt;50<sup>th</sup> (CMS)</div></div></div> | Measure Description      | Plan-Wide                    |        | North Bay Area Rating Region      |        | Rural Upper Central Rating Region |        | Rural Upper North Rating Region                   |  | Benchmark | MY2024 | MY2025 YoY points change | MY2024 | MY2025 | MY2024 | MY2025 | MY2024 | MY2025 | Developmental Screening in the First Three Years of Life (DEV) ^ | <50th | 50th +9.77% | <50th | 50th | 50th | <50th | <50th | <50th | 90 <sup>th</sup> | Lead Screening in Children (LSC) | 75th | 67th +3.16% | 50th | 50th | 50th | 33rd | 75th | 67th | 87 <sup>th</sup> or 75 <sup>th</sup> | Topical Fluoride for Children (TFL) ^ | <50th | <50th +8.67% | <50th | 50th | 50th | 50th | <50th | <50th | 50 <sup>th</sup> – MPL or >50 <sup>th</sup> (CMS) | Cervical Cancer Screening (CCS-E) | 50th (Hybrid) | 25th -11.04% | 75th (Hybrid) | 50th | <25th (Hybrid) | <25th | 25th (Hybrid) | 50th | 25 <sup>th</sup> or 33 <sup>rd</sup> | Measure Description | Plan-Wide |  | North Bay Area Rating Region |  | Rural Upper Central Rating Region |  | Rural Upper North Rating Region |  | Benchmark | MY2024 | MY2025 YoY points change | MY2024 | MY2025 | MY2024 | MY2025 | MY2024 | MY2025 | Follow-Up After Emergency Department Visit for Mental Illness - 30-Days (FUM-30) | <25th | <25th +21.25% | <25th | <25th | <25th | <25th | <25th | 33rd | 90 <sup>th</sup> | Breast Cancer Screening (BCS-E) | 50th | 33rd -2.86% | 50th | 50th | <25th | <25th | 25th | <25th | 87 <sup>th</sup> or 75 <sup>th</sup> |
| Measure Description                                                                        | Plan-Wide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                          | North Bay Area Rating Region |        | Rural Upper Central Rating Region |        | Rural Upper North Rating Region   |        | Benchmark                                         |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
|                                                                                            | MY2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | MY2025 YoY points change | MY2024                       | MY2025 | MY2024                            | MY2025 | MY2024                            | MY2025 |                                                   |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Developmental Screening in the First Three Years of Life (DEV) ^                           | <50th                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 50th +9.77%              | <50th                        | 50th   | 50th                              | <50th  | <50th                             | <50th  | 90 <sup>th</sup>                                  |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Lead Screening in Children (LSC)                                                           | 75th                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 67th +3.16%              | 50th                         | 50th   | 50th                              | 33rd   | 75th                              | 67th   | 87 <sup>th</sup> or 75 <sup>th</sup>              |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Topical Fluoride for Children (TFL) ^                                                      | <50th                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <50th +8.67%             | <50th                        | 50th   | 50th                              | 50th   | <50th                             | <50th  | 50 <sup>th</sup> – MPL or >50 <sup>th</sup> (CMS) |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Cervical Cancer Screening (CCS-E)                                                          | 50th (Hybrid)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 25th -11.04%             | 75th (Hybrid)                | 50th   | <25th (Hybrid)                    | <25th  | 25th (Hybrid)                     | 50th   | 25 <sup>th</sup> or 33 <sup>rd</sup>              |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Measure Description                                                                        | Plan-Wide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                          | North Bay Area Rating Region |        | Rural Upper Central Rating Region |        | Rural Upper North Rating Region   |        | Benchmark                                         |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
|                                                                                            | MY2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | MY2025 YoY points change | MY2024                       | MY2025 | MY2024                            | MY2025 | MY2024                            | MY2025 |                                                   |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Follow-Up After Emergency Department Visit for Mental Illness - 30-Days (FUM-30)           | <25th                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <25th +21.25%            | <25th                        | <25th  | <25th                             | <25th  | <25th                             | 33rd   | 90 <sup>th</sup>                                  |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |
| Breast Cancer Screening (BCS-E)                                                            | 50th                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 33rd -2.86%              | 50th                         | 50th   | <25th                             | <25th  | 25th                              | <25th  | 87 <sup>th</sup> or 75 <sup>th</sup>              |  |           |        |                          |        |        |        |        |        |        |                                                                  |       |             |       |      |      |       |       |       |                  |                                  |      |             |      |      |      |      |      |      |                                      |                                       |       |              |       |      |      |      |       |       |                                                   |                                   |               |              |               |      |                |       |               |      |                                      |                     |           |  |                              |  |                                   |  |                                 |  |           |        |                          |        |        |        |        |        |        |                                                                                  |       |               |       |       |       |       |       |      |                  |                                 |      |             |      |      |       |       |      |       |                                      |

| AGENDA ITEM                                                                                | DISCUSSION / CONCLUSIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VI.B Healthcare Effectiveness Data Information Set (HEDIS ®) Annual Summary of Performance | <b>Key Takeaways</b> <ul style="list-style-type: none"> <li>High achievement or year-over-year improvement on MCAS Withhold measures at the Regional Level is the highest priority for network – this will drive success in all DHCS Accountability Programs and Partnership’s NCQA Star Rating.</li> <li>2026 Priority Improvement Areas for Rating Regions, provider specific priorities will be aligned with the strategy shown below.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                            | <b>North Bay Area</b><br>(Marin, Napa, Solano, Sonoma, Yolo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <b>Rural Upper Central</b><br>(Butte, Colusa, Glenn, Nevada, Placer, Plumas, Sierra, Sutter, Tehama, Yuba)                                                                                                                                                                                                                                                                                                                                                                                                                      | <b>Rural Upper North</b><br>(Del Norte, Humboldt, Lake, Lassen, Mendocino, Modoc, Shasta, Siskiyou, Trinity)                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                            | <b>Towards Regional 67<sup>th</sup> percentile:</b> <ol style="list-style-type: none"> <li>Glycemic Status Assessment for Patients With Diabetes (&gt;9%) (GSD)</li> <li>Child and Adolescent Well-Care Visits (WCV)</li> <li>Lead Screening in Children (LSC)</li> <li>Cervical Cancer Screening (CCS-E)</li> <li>Follow-Up After Emergency Department Visit for Substance Use - 30-Days (FUA-30)</li> <li>Colorectal Cancer Screening (COL) – <b>New in MY2026!</b></li> </ol>                                                                                                                                                                                                                                                                                                                                                                                                    | <b>Towards Regional 50th percentile:</b> <ol style="list-style-type: none"> <li>Glycemic Status Assessment for Patients With Diabetes (&gt;9%) (GSD) – <b>select counties towards 67<sup>th</sup></b></li> <li>Controlling High Blood Pressure (CBP)</li> <li>Child and Adolescent Well-Care Visits (WCV)</li> <li>Immunizations for Adolescents - Combination 2 (IMA-E)</li> <li>Timeliness of Prenatal Care (PPC-Pre)</li> <li>Well-Child Visits in the First 30 Months of Life - 6+ visits in 0-15 months (W30-6)</li> </ol> | <b>Towards Regional 67th percentile:</b> <ol style="list-style-type: none"> <li>Glycemic Status Assessment for Patients With Diabetes (&gt;9%) (GSD)</li> <li>Controlling High Blood Pressure (CBP)</li> <li>Child and Adolescent Well-Care Visits (WCV)</li> <li>Immunizations for Adolescents - Combination 2 (IMA-E)</li> <li>Timeliness of Prenatal Care (PPC-Pre)</li> <li>Well-Child Visits in the First 30 Months of Life - 2+ visits in 15-30 months (W30-2)</li> </ol> |
|                                                                                            | <b>Discussion</b><br><p>Data availability and completeness are significant factors for follow-up after emergency department visits for mental illness. It was noted Rural Upper North appeared to perform comparatively well, possibly due to the Wellness and Recovery (W&amp;R) benefit may contributing to the result, but (W&amp;R) implementation differs by region with some counties administering the program. There were concerns performance could worsen in the next year depending on how the benefit is administered and whether comparable support is available across regions.</p> <p><b>Questions can be directed to</b><br/> <b>HEDIS Team:</b> <a href="mailto:hedisteam@partnershiphp.org">hedisteam@partnershiphp.org</a><br/> <a href="#">MY2025 MCAS Annual Summary of Performance</a><br/> <a href="#">MY2025 NCQA HPA Annual Summary of Performance</a></p> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

| AGENDA ITEM                | ADJOURMENT                                                          |
|----------------------------|---------------------------------------------------------------------|
| PAC adjourned at 9:03 a.m. | Next Physician Advisory Committee announced for September 12, 2026. |

**For Signature Only**

The foregoing minutes were APPROVED AS PRESENTED on 09/09/2026  
Date

  
Angela Brennan, D.O., Committee Chairperson

The foregoing minutes were APPROVED WITH MODIFICATION on \_\_\_\_\_  
Date

\_\_\_\_\_  
Angela Brennan, D.O., Committee Chairperson